Erasca Receives FDA Fast Track Designation for ERAS-0015 in Metastatic Pancreatic Adenocarcinoma

Erasca, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to its investigational therapy, ERAS-0015, for the treatment of patients with metastatic pancreatic adenocarcinoma. This designation aims to facilitate development and expedite the review of therapies addressing serious conditions with unmet medical needs.